MA50341A - Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique - Google Patents

Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique

Info

Publication number
MA50341A
MA50341A MA050341A MA50341A MA50341A MA 50341 A MA50341 A MA 50341A MA 050341 A MA050341 A MA 050341A MA 50341 A MA50341 A MA 50341A MA 50341 A MA50341 A MA 50341A
Authority
MA
Morocco
Prior art keywords
prednisone
administration
treatment
methods
prostate cancer
Prior art date
Application number
MA050341A
Other languages
English (en)
French (fr)
Inventor
Namphuong Tran
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of MA50341A publication Critical patent/MA50341A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Engineering & Computer Science (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050341A 2017-10-11 2018-02-08 Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique MA50341A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762570781P 2017-10-11 2017-10-11

Publications (1)

Publication Number Publication Date
MA50341A true MA50341A (fr) 2020-08-19

Family

ID=61283312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050341A MA50341A (fr) 2017-10-11 2018-02-08 Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique

Country Status (16)

Country Link
US (2) US20190105332A1 (cg-RX-API-DMAC7.html)
EP (1) EP3694604A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020536903A (cg-RX-API-DMAC7.html)
KR (1) KR20200068689A (cg-RX-API-DMAC7.html)
CN (1) CN111542373A (cg-RX-API-DMAC7.html)
AU (1) AU2018347804A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007090A2 (cg-RX-API-DMAC7.html)
CA (1) CA3077678A1 (cg-RX-API-DMAC7.html)
EA (1) EA202090916A1 (cg-RX-API-DMAC7.html)
IL (1) IL273826A (cg-RX-API-DMAC7.html)
JO (1) JOP20200072A1 (cg-RX-API-DMAC7.html)
MA (1) MA50341A (cg-RX-API-DMAC7.html)
MX (1) MX2020003830A (cg-RX-API-DMAC7.html)
PH (1) PH12020550151A1 (cg-RX-API-DMAC7.html)
UA (1) UA124865C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019074536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
JP2023524794A (ja) * 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ.ベー. アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
CN117120034A (zh) * 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898495B (zh) * 2012-11-12 2014-11-26 浙江神洲药业有限公司 醋酸阿比特龙酯的制备方法

Also Published As

Publication number Publication date
WO2019074536A1 (en) 2019-04-18
UA124865C2 (uk) 2021-12-01
PH12020550151A1 (en) 2021-02-08
JOP20200072A1 (ar) 2020-04-29
US20200069704A1 (en) 2020-03-05
AU2018347804A1 (en) 2020-04-16
IL273826A (en) 2020-05-31
CA3077678A1 (en) 2019-04-18
BR112020007090A2 (pt) 2020-09-24
MX2020003830A (es) 2020-11-06
KR20200068689A (ko) 2020-06-15
CN111542373A (zh) 2020-08-14
EP3694604A1 (en) 2020-08-19
EA202090916A1 (ru) 2020-12-11
US20190105332A1 (en) 2019-04-11
JP2020536903A (ja) 2020-12-17

Similar Documents

Publication Publication Date Title
JOP20230159A1 (ar) تركيبة علاجية لسرطان البروستاتا
IL268814A (en) Compositions and methods for treatment of cancer
IL282776A (en) Plasmid constructs for treating cancer and methods of use
EP3638269A4 (en) COMPOSITIONS AND PROCEDURES FOR IMPROVING RADIOTHERAPY AGAINST CANCER
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
EP3506944A4 (en) COMPOSITIONS AND METHODS FOR TREATING TUMOR SUPPRESSOR-DEFICIENT CANCER
IL269157A (en) Compositions and methods for treating cancer
EP3773524A4 (en) TREATMENT OF BREAST CANCER WITH LASOFOXIFEN
EP3681498A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
MA55717A (fr) Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
IL262713A (en) Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases
IL273826A (en) Methods for treating prostate cancer using abiraterone acetate and prednisone with androgen deprivation therapy
EP3347010A4 (en) SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER
EP3688023A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
MA47436A (fr) Traitement de la mucopolysaccharidose i avec une alpha-l-iduronidase glycosylée entièrement humaine (idua)
IL282948A (en) Compositions and methods for treating cancer
EP3720427A4 (en) COMPOSITIONS FOR TREATMENT OF BREAST AND PROSTATE CANCER
EP3794040A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER
EP4034163A4 (en) METHOD FOR TREATING METASTASIC TRIPLE NEGATIVE BREAST CANCER USING ANTI-PD-1 ANTIBODIES
EP3731853A4 (en) BREAST CANCER AND CHRONIC DISEASE TREATMENT METHOD
EP3987032A4 (en) Methods and compositions for the treatment of cancer
BR112022021732A2 (pt) Tratamentos de câncer de próstata com combinações de acetato de abiraterona e niraparibe
EP3672582A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP3490584A4 (en) METHOD AND COMPOSITIONS FOR TREATING MELANOMA
EP3955943A4 (en) Gmci and ddri combination therapy for treating cancer